Slide 1: Next-generation assistive technology and data measurement
For personal use only Next-generation assistive technology and data measurement INVESTOR PRESENTATION APRIL 2024 CONTROLBIONICS.COM | ASX:CBL
Slide 2: Disclaimer
Disclaimer This presentation is intended to provide a general outline only and is not intended to be a definitive statement on the subject matter covered in it. The For personal use only information in this presentation, whether written or verbal, has been prepared without taking into account the co
Slide 3: Proven core technology now with infinite possibilities
INTRODUCTION Proven core technology now with For personal use only infinite possibilities We are empowering communication and enhancing lives with a vision to revolutionise medicine, sports science, rehabilitation and more with our next- generation EMG technology
Slide 4: On the cusp of rapid global growth
INTRODUCTION On the cusp of rapid global growth For personal use only A proven medical device company with sizeable global sales of core products that we design and manufacture 20 years of Regulatory Core business Blue sky and Many levers for Near cash flow expertise with our clearance and continues
Slide 5: EMG technology is at the heart of our solutions
INTRODUCTION EMG technology is at the heart of our solutions For personal use only An EMG signal is Our patented code detected. creates a “switch” to operate devices Your brain sends a To move your finger, Our core IP uses smart Users can type, generate thought like “move my an electrical signal is
Slide 6: The evolution of our core IP
INTRODUCTION The evolution of our core IP Smaller, wireless and wearable For personal use only NEUROEDUCATOR NEUROSTRIP One of the first prototype systems in A wireless, wearable NeuroNode was Just launched in 2023, the NeuroStrip the NeuroEDUCATOR series was first launched in 2017. Using our IP, we
Slide 7: Solutions
Solutions For personal use only Assistive Communication Assistive Mobility Data Measurement
Slide 8: Core products and those newly launched
PRODUCT OVERVIEW Core products and those newly launched Currently assisting those disabled and leaping to new untapped markets For personal use only CUSTOMERS CURRENT CORE PRODUCTS NEW PRODUCTS Disabled and diseased Speech-generating solutions with flexible access methods (touch, eye, EMG) Standalon
Slide 9: Types of technology access
ASSISTIVE COMMUNICATION 3 types of technology access Flexible access to communication and speech-generating technology for those who cannot speak For personal use only TOUCH ACCESS For those who can touch a computer screen to select letters, Our key communication words, phrases, or symbols to learn
Slide 10: Our core IP remains innovative and without major competition even today
ASSISTIVE COMMUNICATION Our core IP remains innovative and without For personal use only major competition even today Those with degenerative neurological conditions, spinal cord injuries, cerebral palsy, and other conditions with movement restrictions can now access a computer, phone, tablet, and o
Slide 11: Our flagship product is the world's fastest, lowest-fatigue eye-tracking system
ASSISTIVE COMMUNICATION For personal use only Our flagship product is the world’s fastest, lowest- fatigue eye-tracking system, combining a camera, computer and NeuroNode (EMG/spatial) control This 3 in 1 solution suits those living with paralysis and loss of speech. Unlike other technologies, no mo
Slide 12: Assistive communication product suite
ASSISTIVE COMMUNICATION PRODUCT SUITE A voice for those without Bundle with a NeuroNode for faster, less tiring and easier communication For personal use only USER TYPES A UnoTouch upgrade Includes all 3 access types Entry level access for Entry level for those who A user’s condition will determine
Slide 13: Why our communication solutions are better
ASSISTIVE COMMUNICATION Why our communication solutions are better For personal use only Other Providers Control Bionics Benefit to the customer Require a keyboard, Uses EMG and/or eye tracking. Proven to be both faster and less fatiguing in multiple studies. It mouse, joystick, also reduces repetit
Slide 14: Assistive mobility: a new world first
ASSISTIVE MOBILITY A new world first Independent, safe travel within the home autonomous wheelchair For personal use only Partnering with Deakin University, we made the world’s first upgrade for powered wheelchairs, so the user’s intentions can control them Watch Me DROVE is a patent pending module
Slide 15: The new NeuroStrip is a game-changer
BEYOND ASSISTIVE TECHNOLOGY The new NeuroStrip is a game-changer For personal use only We are on a path to revolutionise new markets such as health diagnostics, sports science, critical care and more with the new miniaturisation of our world-class, award- A lightweight, flexible winning core technol
Slide 16: NeuroStrip features and benefits
BEYOND ASSISTIVE TECHNOLOGY NeuroStrip features and benefits For personal use only FEATURE BENEFIT Small, light, flexible and non-invasive. Increased choice of placement where At 3g, it weighs less than a piece of you want to switch with, monitor or NeuroStrip paper and is 4cm long. improve. It’s al
Slide 17: Regulatory approvals
PRODUCT Regulatory approvals For personal use only US Australia Japan UK Europe Regulatory Scheme FDA TGA PMDA MHRA CE Mark NeuroNode DROVE NeuroStrip * May require further approvals if the product use materially changes Approved Pending or near-term application Yet to be approved
Slide 18: Assistive Technology Market
For personal use only Assistive Technology Communication Market Mobility
Slide 19: Our users
Our users Our devices help people of all ages living with For personal use only conditions like ALS/Motor Neuron Disease (MND), Spinal Muscular Atrophy, Cerebral Palsy, and Spinal Cord Injury to control communication technology US AND AUSTRALIAN Amyotrophic Lateral Sclerosis (ALS) SALES BY CONDITION
Slide 20: Minimum $1.3bn global market opportunity p.a.
Minimum $1.3bn global market opportunity p.a. For personal use only An underserved niche market with few competitors and plenty of room for growth in the US, UK, Japan, Australia and select European countries First sales in Japan About 66,000 new cases are diagnosed each year for Well established in
Slide 21: Minimum $100 million market opportunity p.a.
Minimum $100 million market opportunity p.a. For personal use only This is a new market for us where our add-on module to powered wheelchairs allows users to independently and safely navigate their homes The market opportunity is based on a 1% penetration of new global annual sales. 2 million Powere
Slide 22: Current Business Model
For personal use only Current Business Model A retail business model where our sales team work with prescribers to offer just assistive communication solutions.
Slide 23: The market's most personalised solution
ASSISTIVE COMMUNICATION The market’s most OUR PRESCRIBERS Prescribers demonstrate and recommend our solutions. They include Speech personalised solution Language Pathologists (SLPs), industry For personal use only bodies, clinics, schools, hospitals and more LANGUAGE SYSTEM Our catalogue of syntheti
Slide 24: Funding overview
ASSISTIVE COMMUNICATION Funding overview For personal use only At least 75% of our sales are Other through a person’s insurer 8% other 13% Federal 35% Medicare / 3rd Party Billing* Medicaid / 29% Veteran Affairs / STAPP (Texas) USA AUSTRALIA Private pay Private Insurance NDIS National Disability 12%
Slide 25: Growth Strategy
For personal use only Growth Strategy A new wholesale business model where we work with resellers and partners to offer more products with more uses in more geographical locations, generating new income streams and recurring revenue.
Slide 26: New wholesale strategy for growth
GROWTH STRATEGY OUR SOLUTIONS RESELLER OR New wholesale USER PARTNER strategy for For personal use only growth SOFTWARE HARDWARE SUPPORT 24/7 Continued innovation NEUROSTRIP means we can further diversify the use of our NEURONODE ADVANTAGE DROVE ADVANTAGE NEUROSTRIP ADVANTAGE products and enter new
Slide 27: Multiple levers for growth
GROWTH STRATEGY Multiple levers for growth For personal use only CURRENT SALES STATUS NEW GEOGRAPHIES NEW CHANNEL PARTNERS NEW USE TYPE Japan was the first market Our next focus is the UK and Currently building distributor No - assistive for our new NeuroNode select continental European partnerships
Slide 28: Blue sky growth strategy with NeuroStrip
GROWTH STRATEGY Blue sky growth strategy with NeuroStrip For personal use only USE TYPE FOR WHAT OUTCOME EASE OF MARKET ENTRY SELLING POINTS REGULATORY CURRENT BUSINESS / PRODUCT READINESS REQUIREMENTS DEVELOPMENT OPPORTUNITIES CBL has existing track record None In discussions with existing Sports s
Slide 29: Blue sky growth strategy with NeuroStrip
GROWTH STRATEGY Blue sky growth strategy with NeuroStrip For personal use only USE TYPE FOR WHAT OUTCOME EASE OF MARKET ENTRY SELLING POINTS REGULATORY CURRENT BUSINESS / PRODUCT READINESS REQUIREMENTS DEVELOPMENT OPPORTUNITIES Dysphagia sEMG biofeedback is used to Established market however new Lig
Slide 30: Roadmap
GROWTH STRATEGY Roadmap For personal use only Q4 FY24 Q1 FY25 Q2 FY25 Q3 FY25 Q4 FY25 DROVE TGA approval First sales DROVE expected US breakeven expected Final tranche of US FDA submission for DROVE research grant payment for DROVE NeuroStrip customer trials New partnerships for Japan breakeven expe
Slide 31: Financial Performance
For personal use only Financial Performance
Slide 32: Financials
FINANCIALS REVENUE (A$ m) EBITDA ($A m) 6 5 25% 0 -1 Gaining traction year on year For personal use only 4 -2 3 -3 2 -4 300 systems sold in our key markets in FY23. 1 -5 FY23 revenue up an impressive 25% over FY22. -6 0 2021 2022 2023 2021 2022 2023 US is the strongest market as the strength of our
Slide 33: Financials: FY24 1H results
3.5 3.0 FINANCIALS 2.5 2.0 FY24 1H results Total Revenues of $3.5m for the period. This compares to H1 For personal use only REVENUE (A$ m) 1.5 2023 as follows: 1.0 Continued reduction in losses in EBITDA over the same 0.5 comparative period in 2023 ($1.8m from $2.5m). 0.0 H1 FY21 H1 FY22 H1 FY23 H1
Slide 34: Company
For personal use only Company
Slide 35: Experienced leadership
PEOPLE Experienced leadership For personal use only BOARD Roger Hawke Jeremy Steele Peter Ford Chairman Managing Director Founder & Independent CEO Non Executive Director Non Executive Director Prof Rob Heard Damian Lismore Brett Crowley Independent Independent Company Secretary Non Executive Direct
Slide 36: Corporate Summary
Corporate Summary FINANCIAL INFORMATION For personal use only TOP SHAREHOLDERS Phoenix Development 18.32% Share price (19/4/24) A$0.044 Nightingale Partners 12.47% Shares on issue 170.7 million Peter Shann Ford 11.50% Market capitalisation A$7.51 million Cash (31/03/24) A$0.88 million Top 20 hold 73
Slide 37: Get in touch
Get in touch For personal use only COMPANY INVESTOR RELATIONS JEREMY STEELE JOE DURAK CEO EXECUTIVE DIRECTOR & FOUNDER CONTROL BIONICS LYNX ADVISORS jsteele@controlbionics.com joe@lynxadvisors.com.au +61 433 229 470 +61 414 465 582 CONTROLBIONICS.COM | ASX:CBL
Slide 38: Additional Information
For personal use only Additional Information
Slide 39: NeuroStrip helps elite athletes jump higher and reduce injury
BEYOND ASSISTIVE TECHNOLOGY NeuroStrip helps elite athletes jump higher and reduce injury For personal use only NEUROBOUNCE USES OUR TECHNOLOGY A professional sports scientist currently uses our EMG technology to train the brain of his athletes so the motor neuron recruitment to muscles used in jump
Slide 40: Our technology is years in the making
ABOUT Our technology is 20 years in the making For personal use only “Peter Ford, the founder, $20.79m was inspired by Stephen Hawking and how there had NeuroNode to be a better way to help Registration with UK people like Stephen Hawking Neurostrip Medical participate more in society. Roger Hawke J